Welcome to our dedicated page for Immunoprecise news (Ticker: IPA), a resource for investors and traders seeking the latest updates and insights on Immunoprecise stock.
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd. (IPA), reports developments in Bio-Native AI, biologics discovery, and AI-driven drug development. Company updates focus on the HYFT® technology stack and the LensAI™ platform, which combine computational analysis with wet-lab validation for epitope mapping, de novo molecular design, in silico vaccine exploration, immunogenicity screening, and population-scale biologics analytics.
Recurring news also covers earnings releases, platform commercialization, partnership and customer activity, and portfolio initiatives such as B Cell Llama™ nanobody discovery and dengue vaccine research. Corporate updates include the transition from the ImmunoPrecise brand to MindWalk, the Nasdaq ticker change to HYFT, and portfolio refinements such as the divestiture of the Netherlands antibody-discovery operations.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announced strong neutralizing data for its PolyTope® TATX-03 antibody cocktail against the SARS-CoV-2 Omicron variant. The company claims TATX-03 is the only first-generation cocktail effective against all tested variants. Following positive in vitro results, IPA plans to submit an Investigational New Drug (IND) application to the FDA. Talem Therapeutics, a subsidiary, filed a patent application for TATX-03, aiming for protection in significant markets. Results indicate potential for broad therapeutic use, even as more variants emerge.
Summary not available.
ImmunoPrecise Antibodies Ltd. (IPA) announced the grant of 15,000 stock options to a company officer on January 13, 2022. Each option, priced at Cdn $8.30, allows for the acquisition of up to 15,000 common shares, with a vesting schedule of one-third every two months. This strategic move enhances the company's ability to attract and retain talent while aligning employee interests with shareholder value. ImmunoPrecise focuses on advancing innovative therapeutic antibody discovery to tackle complex disease targets.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announced the approval of 170,000 stock options by its board of directors on January 7, 2022. These options are granted to certain officers and are exercisable at Cdn $7.94 per share for five years. The vesting schedule will allow one third of the options to vest every six months. ImmunoPrecise continues to focus on transforming antibody discovery with a comprehensive service suite aimed at optimizing genetic diversity and epitope coverage for its partners.
ImmunoPrecise Antibodies Ltd. (IPA) announces the approval of 28,250 stock options for its non-executive directors, following the recent Annual General Meeting. Each director received 5,650 options, with Ms. Anna Pettersson receiving an additional 11,300 options. The options are exercisable for five years at an exercise price of Cdn $6.89 per share, with quarterly vesting. This action reflects the company’s commitment to rewarding its board members and aligning their interests with shareholders in the dynamic therapeutic antibody sector.
ImmunoPrecise Antibodies (IPA) has partnered with ChemPartner Biologics to manufacture its PolyTope® TATX-03 therapeutic antibody cocktail aimed at combating SARS-CoV-2 variants. This collaboration allows for scalable production of the antibodies, ensuring a rapid response to evolving variants. IPA believes this partnership is vital due to growing concerns about the efficacy of existing vaccines and therapies against new COVID-19 strains. Both companies express confidence in their ability to meet manufacturing demands, with ChemPartner’s facilities supporting IPA’s clinical development needs.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) reported its second quarter fiscal 2022 results, with revenues of $4.7 million, a slight decline of 0.7% from last year. The company recorded a net loss of $5.0 million, a significant increase from $463,584 in the previous year. Research and development expenses surged to $2.8 million from $1.1 million. Despite the financial challenges, IPA holds cash reserves of $38.4 million. The company continues to focus on pipeline expansion and strategic investments in R&D.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) will host an earnings conference call on December 13, 2021, to discuss its financial results for the second quarter of fiscal year 2022. The call starts at 4:30 p.m. Eastern time and will include a Q&A session. Investors can submit questions ahead of time via email. Details for joining the call include toll-free and international dial-in numbers along with a conference ID. The results will be announced in a press release prior to the call.
ImmunoPrecise Antibodies Ltd. (IPA) announced significant progress in its Polytope™ development program, aimed at combating SARS-CoV-2. Key milestones include FDA assessment of its pre-investigational new drug application and the commencement of preclinical safety studies. The Polytope™ antibody cocktail has shown effectiveness against several variants of concern, including the Lambda and Mu variants. Additionally, IPA is analyzing the Omicron variant and has improved the protein homogeneity in its antibody cocktail for better clinical production. The company remains optimistic about its COVID-19 therapeutic.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is set to present at the Benchmark Company’s Discovery One-on-One Virtual Video Investor Conference on December 2, 2021. The conference aims to showcase dynamic publicly traded micro-cap companies. The Benchmark Company, founded in 1988 and headquartered in New York City, provides a full suite of investment banking and brokerage services. ImmunoPrecise focuses on antibody discovery, offering services to optimize genetic diversity and epitope coverage for disease targets.